White matter changes in schizophrenia evidence for myelin-related dysfunction

Archives of General Psychiatry

Volumn 60, Issue 5, 2003, Pages 443-456

  Davis, Kenneth L ^a   Stewart, Daniel G ^a   Friedman, Joseph I ^a,c   Buchsbaum, Monte ^a   Harvey, Philip D ^a   Hof, Patrick R ^a   Buxbaum, Joseph ^a   Haroutunian, Vahram ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Pilgrim Psychiatric Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN;

BRAIN DEATH; BRAIN DYSFUNCTION; BRAIN REGION; DEMYELINATING DISEASE; HUMAN; MYELINATION; OLIGODENDROGLIA; REVIEW; SCHIZOPHRENIA; WHITE MATTER;

AGE FACTORS; ANISOTROPY; BRAIN; CELL DEATH; DEMYELINATING DISEASES; HUMANS; MYELIN SHEATH; NERVE FIBERS, MYELINATED; OLIGODENDROGLIA; PROTEIN ARRAY ANALYSIS; SCHIZOPHRENIA;

EID: 0038643584     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.60.5.443     Document Type: Review

References (276)

1. Liddle PF. Functional imaging: schizophrenia. Br Med Bull. 1996;52:486-494.
2. McClure RJ, Keshavan MS, Pettegrew JW. Chemical and physiologic brain imaging in schizophrenia. Psychiatr Clin North Am. 1998; 21:93-122.
3. Frith C, Dolan R. The role of the prefrontal cortex in higher cognitive functions. Cogn Brain Res. 1996;5:175-181.
4. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997;349:1730-1734.
5. Tcherepanov AA, Sokolov BP. Age-related abnormalities in expression of mRNAs encoding synapsin 1A, synapsin 1B, and synaptophysin in the temporal cortex of schizophrenics. J Neurosci Res. 1997;49:639-644.
6. R 38,000 characteristic of presynaptic vesicles. Cell. 1985;41:1017-1028.
7. Eastwood SL, Burnet PWJ, McDonald B, Clinton J, Harrison PJ. Synaptophysin gene expression in human brain: a quantitative in situ hybridization and immunocytochemical study. Neuroscience. 1994;59:881-892.
8. Eastwood SL, Burnet PWJ, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 1995;66:309-319.
9. Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989;39:355-361.
10. Masliah E, Terry RD, Alford M, DeTeresa R. Quantitative immunohistochemistry of synaptophysin in human neo-cortex: an alternative method to estimate density of presynaptic terminals in paraffin sections. J Histochem Cytochem. 1990; 38:837-844.
11. Jahn R, Sudhof TC. Synaptic vesicles and exocytosis. Annu Rev Neurosci. 1994;17:219-246.
12. Rosahl TW, Geppert M, Spillane D, Herz J, Hammer RE, Malenka RC, Sudhof TC. Short-term synaptic plasticity is altered in mice lacking synapsin I. Cell. 1993;75:661-670.
13. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P, Davis KL. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997;54:559-566.
14. Eastwood SL, Harrison PJ. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience. 1995;69:339-343.
15. Eastwood SL, Harrison PJ. Detection and quantification of hippocampal synaptophysin messenger RNA in schizophrenia using autoclaved, formalin-fixed, paraffin wax-embedded sections. Neuroscience. 1999;93:99-106.
16. Browning MD, Dudek EM, Rapier JL, Leonard S, Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol Psychiatry. 1993;34:529-535.
17. Young CE, Arima K, Xie J, Hu L, Beach TG, Falkai P, Honer WG. SNAP-25 deficit and hippocampal connectivity in schizophrenia. Cereb Cortex. 1998;8:261-268.
18. Landen M, Davidsson P, Gottfries CG, Grenfeldt B, Stridsberg M, Blennow K. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia. Biol Psychiatry. 1999;46:1698-1702.
19. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity. Arch Gen Psychiatry. 1997; 54:943-952.
20. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for "hypofrontality." Mol Psychiatry. 1999;4:39-45.
21. Casanova MF. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull. 1997;23:517-519.
22. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronaf density in prefrontal area 46 in brains from schizophrenic patients: application of a 3-dimensional, stereologic counting method. J Comp Neurol. 1998;392:402-412.
23. Selemon LD, Raikowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. 1995;52:805-820.
24. Pakkenberg B. Total nerve cell number in neocortex in chronic schizophrenic and controls estimated using optical dissectors. Biol Psychiatry. 1993;34:768-772.
25. Williams RW, Rakic P. Elimination of neurons from the rhesus monkey's lateral geniculate nucleus during development. J Comp Neurol. 1988;272:424-436.
26. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry. 1999;45:17-25.
27. Davis SR, Lewis DA. Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry Res. 1995;59:81-96.
28. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE Jr, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry. 1996;53:425-436.
29. Kirkpatrick B, Conley RC, Kakoyannis A, Reep RL, Roberts RC. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: an unbiased cell-counting study. Synapse. 1999; 34:95-102.
30. Pesold C, Davidkova G, Davis JM, Guidotti A, Costa E. A reelin deficit may underlie the neuroanatomical abnormalities observed in the brains of schizophrenic patients. Paper presented at: VIIIth International Congress on Schizophrenia Research; April 28-May 2, 2001; Whistler, British Columbia.
31. Anderson SA, Volk DW, Lewis DA. Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects. Schizophr Res. 1996; 19:111-119.
32. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a post-mortem study of schizophrenia and Huntington's disease. Arch Gen Psychiatry. 1998; 55:215-224.
33. Roberts RC, Conley R, Kung L, Peretti FJ, Chute DJ. Reduced striatal spine size in schizophrenia: a postmortem ultrastructural study. Neuroreport. 1996;7:1214-1218.
34. Brown R, Colter N, Corsellis JAN, Crow TJ, Frith CD, Jagoe R, Johnstone EC, Marsh L. Postmortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry. 1986;43:36-42.
35. Pakkenberg B. Post-mortem study of chronic schizophrenic brains. Br J Psychiatry. 1987;151: 744-752.
36. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry. 1992;42:195-205.
37. Andreasen NC, Flashman L, Flaum M, Arndt S, Swayze V II, O'Leary DS, Ehrhardt JC, Yuh WT. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA. 1994;272:1763-1769.
38. Ward KE, Friedman L, Wise A, Schulz SC. Metaanalysis of brain and cranial size in schizophrenia. Schizophr Res. 1996;22:197-213.
39. Sullivan EV, Shear PK, Lim KO, Zipursky RB, Pfefferbaum A. Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia. Biol Psychiatry. 1996;39:234-240.
40. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE. Cortical gray matter volume deficit in patients with first episode schizophrenia. Am J Psychiatry. 1996;153:1548-1553.
41. Cannon TD, van Erp TGM, Huttunen M, Lonnqvist J, Salonen O, Valanne L, Poutanen V, Standertskjold-Nordenstam CG, Gur RE, Yan M. Regional gray matter, white matter, and cerebrospinal fluid distributions in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry. 1998;55:1084-1091.
42. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157:16-25.
43. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry. 1998;55:346-352.
44. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry. 2000;57:471-480.
45. Buchanan RW, Vladar K, Barta PE, Pearlson GD. Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry. 1998;155:10491055.
46. Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K, Fukuda R, Ron M, Toone B. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. 2001;158:234-243.
47. Breier A, Buchanan RW, ElkashefA, Munson RC, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry. 1992;49:921-926.
48. Wible CG, Shenton ME, Hokama H, Kikinis R, Jolesz FA, Metcalf D, McCarley RW. Prefrontal cortex and schizophrenia: a quantitative magnetic resonance imaging study. Arch Gen Psychiatry. 1995;52:279-288.
49. Ketonen LM, Berg MJ. Clinical Neuroradiology, Vol 5. London, England: Oxford University Press; 1996.
50. Drayer BP. Imaging of the aging brain, I: normal findings. Radiology. 1988;166:785-796.
51. Grafton ST, Sumi SM, Stimac GK, Alvord EC, Shaw C-M, Nochlin D. Comparisons of postmortem magnetic resonance imaging and neuropathologic findings in the cerebral white matter. Arch Neurol. 1991;48:293-298.
52. Persaud R, Russow H, Harvey I, Lewis SW, Ron M, Murray RM, du Boulay G. Focal signal hyperintensities in schizophrenia. Schizophr Res. 1997;27:55-64.
53. Coffey CE, Djang WT, Weiner RD. Subcortical hyperintensities on MRI: a comparison of normal and depressed elderly subjects. Am J Psychiatry. 1990;147:187-189.
54. Harvey I, Ron M, du-Boulay G, Murray RM, Lewis S. White matter abnormalities on magnetic resonance imaging in bipolar patients. Arch Gen Psychiatry. 1990;47:1172-1173.
55. Woodruff PWR, Murray RM. The aetiology of brain abnormalities in schizophrenia. In: Ancill R, ed. Schizophrenia: Exploring the Spectrum of Psychosis. Chichester, England: John Wiley & Sons; 1994:95-114.
56. Sze G, Armond SJ, Brant-Zawadzki M, Davis RL, Norman D, Newton T. Foci of MRI signal (pseudo lesions) anterior to the frontal horns: histological correlations of a normal finding. Am J Radiol 1986;147:331-337.
57. Awad IA, Johnson PC, Spetzler RF, Hudak JA. Incidental sub-cortical lesions identified on magnetic resonance imaging in the elderly, II: postmortem pathological correlations. Stroke. 1986; 17:1090-1097.
58. Kertesz A, Black SE, Tokar G, Benke T, Carr T, Nicholson L, Periventricular and subcortical hyperintensities on magnetic resonance imaging: "rims, caps and unidentified bright objects." Neurology. 1988;45:404-408.
59. Hulshoff HE, Hoek HW, Susser E, Brown AS, Dingemans A, Schnack HG, van Haren NEM, Ramos LMP, Gispen-de Wied CG, Kahn RS. Prenatal exposure to famine and brain morphology in schizophrenia. Am J Psychiatry. 2000;157: 1170-1172.
60. Rivkin P, Kraut M, Barta P, Anthony J, Arria AM, Pearlson G. White matter hyperintensity volume in late-onset and early-onset schizophrenia. Int J Geriatr Psychiatry. 2000;15:10851089.
61. Sachdev P, Brodaty H. Quantitative study of signal hyperintensities on T2-weighted magnetic resonance imaging in late-onset schizophrenia. Am J Psychiatry 1999;156:1958-1967.
62. Tonkonogy JM, Geller JL. Late-onset paranoid psychosis as a distinct clinicopathologic entity: magnetic resonance imaging data in elderly patients with paranoid psychosis of late onset and schizophrenia of early onset. Neuropsychiatry Neuropsychol Behav Neurol. 1999;12:230-235.
63. Miller BL, Benson F, Cummings JL, Neshkes R. Late-life paraphrenia: an organic delusional syndrome. J Clin Psychiatry. 1986;47:204-207.
64. Miller BL, Lesser IM, Boone K, Goldberg M, Hill E, Miller MH, Benson DF, Mehringer M. Brain white-matter lesions and psychosis. Br J Psychiatry. 1989;155:73-78.
65. Miller BL, Lesser IM, Boone K, Hill E, Mehringer CM, Wong K. Brain lesions and cognitive function in late-life psychosis. Br J Psychiatry. 1991;158:76-82.
66. Miller BL, Lesser IM, Mena I, Villanueva-Meyer J, Hill-Gutiérrez E, Boone K. Regional cerebral blood flow in late-life-onset psychosis. Neuropsychiatry Neuropsychol Behav Neurol. 1992; 5:132-137.
67. Lesser IM, Miller BL, Boone KB, Hill-Gutierrez E, Mehringer CM, Wong K, Mena I. Brain injury and cognitive function in late-onset psychotic depression. J Neuropsychiatry Clin Neurosci. 1991; 3:33-40.
68. Breitner JCS, Husain MM, Figiel GS, Krishman KRR, Boyko OB. Cerebral white matter disease in late-onset paranoid psychosis. Biol Psychiatry. 1990;28:266-274.
69. Howard RJ, Forstl H, Naguib M, Burns A, Levy R. First-rank symptoms of Schneider in late paraphrenia: cortical structural correlates. Br J Psychiatry. 1992;160:108-109.
70. Pearlson GD, Garbacz D, Tompkins RH, Ahn HO, Rabins PV. Lateral cerebral ventricular size in late onset schizophrenia. In: Miller NE, Cohen GD, eds. Schizophrenia and Aging. New York, NY: Guildford Press; 1987.
71. Naguib M, Levy R. Late paraphrenia: neuropsychological impairment and structural brain abnormalities on computed tomography. Int J Geriatr Psychiatry. 1987;2:83-90.
72. Rabins P, Pearlson G, Jayaram G, Steele C, Tune L. Increased ventricle-to-brain ratio in lateonset schizophrenia. Am J Psychiatry. 1987; 144:1216-1218.
73. Symonds LL, Olichney JM, Jernigan TL, CoreyBloom J, Healy JF, Jeste DV. Lack of clinically significant gross structural abnormalities in MRIs of older patients with schizophrenia and related psychoses. J Neuropsychiatry Clin Neurosci. 1997;9:251-258.
74. Howard R, Cox T, Almeida O, Mullen R, Graves P, Reveley A, Levy R. White matter signal hyperintensities in the brains of patients with late paraphrenia and the normal, community-living elderly. Biol Psychiatry. 1995;38:86-91.
75. Krull AJ, Press G, Dupont R, Harris MJ, Jeste D. Brain imaging in late-onset schizophrenia and related psychoses. Int J Geriatr Psychiatry. 1991; 6:651-658.
76. Minabe Y, Kadono Y, Kurachi M. A schizophrenic syndrome associated with a midbrain tegmental lesion. Biol Psychiatry. 1990;27:661-663.
77. Larson EB, Katzman R, Brody EM, Drachman DA. First report of the congressionally appointed Advisory Panel on Alzheimer's Disease [letter]. J Gerontol. 1990;45:M120.
78. O'Callaghan E, Larkin C, Redmond O, Stack J, Ennis JT, Waddington JL. "Early-onset schizophrenia" after teenage head injury: a case report with magnetic resonance imaging. Br J Psychiatry. 1988;153:394-396.
79. Foong J, Maier M, Barker GJ, Brocklehurst S, Miller DH, Ron MA. In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. J Neurol Neurosurg Psychiatry. 2000;68:70-74.
80. Foong J, Symms MR, Barker GJ, Maier M, Woermann FG, Miller DH, Ron MA. Neuropathological abnormalities in schizophrenia: evidence from magnetization transfer imaging. Brain. 2001; 124:882-892.
81. Rugg-Gunn FJ, Symms MR, Barker GJ, Greenwood R, Duncan JS. Diffusion imaging shows abnormalities after blunt head trauma when conventional magnetic resonance imaging is normal. J Neurol Neurosurg Psychiatry. 2001;70: 530-533.
82. Ulug AM, Moore DF, Bojko AS, Zimmerman RD. Clinical use of diffusion-tensor imaging for diseases causing neuronal and axonal damage. AJNR Am J Neuroradiol. 1999;20:1044-1048.
83. Taber KH, Pierpaoli C, Rose SE, Rugg-Gunn FJ, Chalk JB, Jones DK, Hurley RA. The future for diffusion tensor imaging in neuropsychiatry. J Neuropsychiatry Clin Neurosci. 2002;14:1-5.
84. Pearlson GD. New insights on the neuroanatomy of schizophrenia. Curr Psychiatry Rep. 1999;1:41-45.
85. Buchsbaum MS, Tang CY, Peled S, Gudbjartsson H, Lu D, Hazlett EA, Downhill J, Haznedar M, Fallon JH, Atlas SW. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia, Neuroreport. 1998;9:425-430.
86. Lim KO, Hedehus M, Moseley M, de Crespigny A, Sullivan EV, Pfefferbaum A. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch Gen Psychiatry. 1999;56:367-374.
87. Shihabuddin L, Buchsbaum MS, Tang C, Brickman AM, Fleischman M, New AS, Siever LJ. Diffusion tensor imaging in schizophrenia and schizophrenia spectrum disorders. Biol Psychiatry. 2000;47(suppl):97S.
88. Agartz I, Andersson JL, Skare S. Abnormal brain white matter in schizophrenia: a diffusion tensor imaging study. Neuroreport. 2001;12:22512254.
89. Pfefferbaum A, Sullivan EV, Hedehus M, Moseley M, Lim KO. Brain gray and white matter transverse relaxation time in schizophrenia. Psychiatry Res. 1999;91:93-100.
90. Steel RM, Bastin ME, McConnell S, Marshall I, Cunningham-Owens DG, Lawrie SM, Johnstone EC, Best JJK. Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res. 2001;106:161-170.
91. Ito R, Melhem ER, Mori S, Eichler FS, Raymond GV, Moser HW. Diffusion tensor brain MR imaging in X-linked cerebral adrenoleukodystrophy. Neurology. 2001;56:544-547.
92. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology. 2001;56: 304-311.
93. Filippi CG, Ulug AM, Ryan E, Ferrando SJ, van Gorp W. Diffusion tensor imaging of patients with HIV and normal-appearing white matter on MR images of the brain. AJNR Am J Neuroradiol. 2001;22:277-283.
94. Pomara N, Crandall DT, Choi SJ, Johnson G, Lim KO. White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatry Res. 2001;106:15-24.
95. Terry RB, DeTeresa R, Hansen LA. Neocortical cell counts in normal human adult aging. Ann Neurol. 1987;21:530-539.
96. Haug H. Brain sizes, surfaces, and neuronal sizes of the cortex cerebri: a stereological investigation of man and his variability and a comparison with some mammals (primates, whales, marsupials, insectivores, and one elephant). Am J Anat. 1987;180:126-142.
97. Peters A, Moss MB, Sethares C. Effects of aging on myelinated nerve fibers in monkey primary visual cortex. J Comp Neurol. 2000;419: 364-376.
98. Coffey CE, Wilkinson WE, Parashos IA, Soady SA, Sullivan RJ, Patterson LJ, Figiel GS, Webb MC, Spritzer CE, Djang WT. Quantitative cerebral anatomy of the aging human brain: a crosssectional study using magnetic resonance imaging. Neurology. 1992;42(3, pt 1):527-536.
99. Murphy DG, DeCarli C, Schapiro MB, Rapoport SI, Horwitz B. Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. Arch Neurol. 1992; 49:839-845.
100. Alves D, Pires MM, Guimaraes A, Miranda MC. Four cases of late onset metachromatic leukodystrophy in a family: clinical, biochemical and neuropathological studies. J Neurol Neurosurg Psychiatry. 1986;49:1417-1422.
101. Fukutani Y, Noriki Y, Sasaki K, Isaki K, Kuriyama M, Kurosawa K, Ida H. Adult-type metachromatic leukodystrophy with a compound heterozygote mutation showing character change and dementia. Psychiatry Clin Neurosci. 1999; 53:425-428.
102. Finelli PF. Metachromatic leukodystrophy manifesting as a schizophrenic disorder: computed tomographic correlation. Ann Neurol. 1985;18: 94-95.
103. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy: insights into the neurobiology of psychosis. Arch Neurol. 1992;49:401-406.
104. Cerizza M, Nemni R, Tamma F. Adult metachromatic leucodystrophy: an underdiagnosed disease? J Neurol Neurosurg Psychiatry. 1987;50: 1710-1712.
105. Skomer C, Stears J, Austin J. Metachromatic leukodystrophy (MLD) XV: adult MLD with focal lesions by computed tomography. Arch Neurol. 1983;40:354-355.
106. Hageman ATM, Gabreels FJM, de Jong JGN, Gabreels-Festen AAW, van der Berg CJMG, van Oost BA, Wevers RA. Clinical symptoms of adult metachromatic leukodystrophy and arylsulfatase A pseudodeficiency. Arch Neurol. 1995;52:408-413.
107. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP. Adrenoleukodystrophy: a clinical and pathological study of 17 cases. Arch Neurol 1975;32:577-591.
108. Shapiro EG, Lockman LA, Knopman D, Krivit W. Characteristics of the dementia in late-onset metachromatic leukodystrophy. Neurology. 1994; 44:662-665.
109. Johannsen P, Ehlers L, Hansen HJ. Dementia with impaired temporal glucose metabolism in lateonset metachromatic leukodystrophy. Dement Geriatr Cogn Disord. 2001;12:85-88.
110. D'Hooge R, Van Dam D, Franck F, Gieselmann V, Oe Deyn PP. Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. Brain Res. 2001;907:35-43.
111. Beatty WW. Cognitive and emotional disturbances in multiple sclerosis. Neurol Clin. 1993; 11:189-204.
112. Honer WG, Hurwitz T, Li DK, Palmer M, Paty DW. Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Arch Neurol. 1987;44:187-190.
113. Reischies FM, Baum K, Brau H, Hedde JP, Schwindt G. Cerebral magnetic resonance imaging findings in multiple sclerosis: relation to disturbance of affect, drive, and cognition. Arch Neurol. 1988;45:1114-1116.
114. Thorpe JW, Barker GJ, Jones SJ, Moseley I, Losseff N, MacManus DG, Webb S, Mortimer C, Plummer DL, Tofts PS. Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry. 1995;59:487-492.
115. Gass A, Barker GJ, Kidd D, Thorpe JW, MacManus D, Brennan A, Tofts PS, Thompson AJ, McDonald WI, Miller DH. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol. 1994;36:62-67.
116. Dousset V, Gayou A, Brochet B, Caille JM. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology. 1998;51:1150-1155.
117. Mottershead JP, Thornton JS, Clemence M, Scaravilli F, Newcombe J, Cuzner ML, Barker GJ, Tofts PS, Parker GJM, Ordidge RJ, Miller DH, McDonald WI. Correlation of spinal cord axonal density with post mortem NMR measurements in multiple sclerosis and controls [abstract]. Proc Int Soc Magn Reson Med. 1998;6:2163.
118. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, Polman CH, Barkhof F. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology. 1998;50: 1282-1288.
119. Sperling RA, Guttmann CR, Hohol MJ, Warfield SK, Jakab M, Parente M, Diamond EL, Daffner KR, Olek MJ, Orav EJ, Kikinis R, Jolesz FA, Weiner HL. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol. 2001; 58:115-121.
120. Rao SM. A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. New York, NY: National Multiple Sclerosis Society; 1990.
121. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis, I: frequency, patterns, and prediction. Neurology. 1991;41:685-691.
122. Ron MA, Callanan MM, Warrington EK. Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study. Psychol Med. 1991; 21:59-68.
123. Peyser JM, Rao SM, LaRocca NG, Kaplan E. Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol. 1990;47:94-97.
124. Comi G, Filippi M, Martinelli V, Campi A, Rodegher M, Alberoni M, Sirabian G, Canal N. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci. 1995;132:222-227.
125. Medaer R, Nelissen E, Appel B, Swerts M, Geutjens J, Callaert H. Magnetic resonance imaging and cognitive functioning in multiple sclerosis. J Neurol. 1987;235:86-89.
126. Swirsky-Sacchetti T, Mitchell DR, Seward J, Gonzales C, Lublin F, Knobler R, Field HL. Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology. 1992;42:1291-1295.
127. Rao SM, Leo GJ, Haughton VM, St AubinFaubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989;39: 161-166.
128. Hohol MJ, Guttmann CR, Orav J, Mackin GA, Kikinis R, Khoury SJ, Jolesz FA, Weiner HL. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997;54:1018-1025.
129. Arnett PA, Rao SM, Bernardin L, Grafman J, Yetkin FZ, Lobeck L. Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology. 1994;44:420-425.
130. Foong J, Rozewicz L, Quaghebeur G, Davie CA, Kartsounis LD, Thompson AJ, Miller DH, Ron MA. Executive function in multiple sclerosis: the role of frontal lobe pathology. Brain. 1997;120(pt 1): 15-26.
131. Demaree HA, Gaudino EA, DeLuca J, Ricker JH. Learning impairment is associated with recall ability in multiple sclerosis. J Clin Exp Neuropsychol. 2000;22:865-873.
132. Gaudino EA, Chiaravalloti ND, DeLuca J, Diamond BJ. A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:32-44.
133. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zidenbos A, Paus T, Evans AC, Rapoport JL. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci. 1999;2:861-863.
134. Yakovlev PI, Lecours AR. Regional Development of the Brain in Early Life. Oxford, England: Blackwell Scientific Publications; 1967:3-70.
135. Benes FM. Myelination of cortical-hippocampal relays during late adolescence: anatomical correlates to the onset of schizophrenia. Schizophr Bull. 1989;15:585-594.
136. Benes FM, Turtle M, Khan Y, Farol P. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch Gen Psychiatry. 1994;51:477-484.
137. Huttenlocher PR. Synaptic density in human frontal cortex: developmental changes and effects of aging. Brain Res. 1979;163:195-205.
138. Huttenlocher PR, de Courten C. The development of synapses in striate cortex of man. Hum Neurobiol. 1987;6:1-9.
139. Peters A, Leahu D, Moss MB, McNally KJ. The effects of aging on area 46 of the frontal cortex of the rhesus monkey. Cereb Cortex. 1994;4: 621-635.
140. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull. 1997;23:437458.
141. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry. 2001;58:461-465.
142. Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry. In press.
143. Baratti C, Barnett A, Pierpaoii C. Comparative MR imaging study of brain maturation in kittens with T1, T2, and the trace of the diffusion tensor. Radiology. 1999;210:133-142.
144. Baratti C, Barnett A, Pierpaoli C. Comparative MRI study of brain maturation using T1, T2, and the diffusion tensor. In: Proceedings of the Fifth Annual Meeting of the ISMRM; April 12-18, 1997; Vancouver, British Columbia. New York, NY: John Wiley & Sons; 1997.
145. Pfefferbaum A, Sullivan EV, Hedehus M, Lim KO, Adalsteinsson E, Moseley M. Age-related decline in brain white matter anisotropy measured with spatially corrected echo-planar diffusion tensor imaging. Magn Reson Med. 2000; 44:259-268.
146. Uranova NA, Orlovskaya DD. Ultrastructural pathology of neuronal connectivity in postmortem brains of schizophrenic patients. Ann Psychiatry. 1996;6:55-72.
147. Uranova NA, Casanova MF, DeVaughn NM, Orlovskaya DD, Denisov DV. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients [letter]. Schizophr Res. 1996;22:81-83.
148. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull. 2001;55:597-610.
149. Miyakawa T, Sumiyoshi S, Deshimaru M, Suzuki T, Tomonari H. Electron microscopic study on schizophrenia: mechanism of pathological changes. Acta Neuropathol. 1972;20:67-77.
150. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry. 1994;36:503-510.
151. Keshavan MS, Rosenberg D, Sweeney JA, Pettegrew JW. Decreased caudate volume in neuroleptic-naive psychotic patients. Am J. Psychiatry. 1998;155:774-778.
152. Orlovskaya DD, Vostrikov VM, Rachmanova VI, Uranova NA. Decreased numerical density of oligodendroglial cells in post-mortem prefrontal cortex in schizophrenia, bipolar affective disorder, and major depression [abstract]. Schizophr Res. 2000;41:105-106.
153. Torrey EF, Webster W, Knable M, Johnston N, Yolken RH. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr Res. 2000;44:151-155.
154. Cotter D, Mackay D, Beasley C, Kervin R, Everall I. Reduced glial density and neuronal volume in major depressive disorder and schizophrenia in the anterior cingulate cortex [abstract]. Schizophr Res. 2000;41:106.
155. Rajkowska-Markov G, Miguel-Hidalgo JJ, Wei J, Stockmeier CA. Reduction in glia distinguishes orbitofrontal region from dorsolateral prefrontal cortex in schizophrenia [abstract]. Soc Neurosci. 1999;25:818.
156. Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthmann H, Karthigasan J, Kirschner DA, Wintergerst ES, Nave K-A, Zielasek J, Toyka KV, Lipp H-P, Schachner M. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron. 1994;13:229246.
157. Bartsch S, Montag D, Schachner M, Bartsch U. Increased number of unmyelinated axons in optic nerves of adult mice deficient in the myelinassociated glycoprotein (MAG). Brain Res. 1997; 762:231-234.
158. Vartanian T, Fischbach G, Miller R. Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. Proc Natl Acad Sci U S A. 1999;96:731-735.
159. Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP, Davis KL. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry. In press.
160. Vartanian T, Corfas G, Li Y, Fischbach GD, Stefansson K. A role for the acetylcholine receptor-inducing protein ARIA in oligodendrocyte development. Proc Natl Acad Sci U S A. 1994;91: 11626-11630.
161. Corfas G, Rosen KM, Aratake H, Krauss R, Fischbach G. Differential expression of ARIA isoforms in the rat brain. Neuron. 1995;14:103-115.
162. Sternberger NH, Quarles RH, Itoyama Y, Webster HD. Myelin-associated glycoprotein demonstrated immunocytochemically in myelin and myelin-forming cells of developing rat. Proc Natl Acad Sci U S A. 1979;76:1510-1514.
163. Gard AL, Maughon RH, Schachner M. In vitro oligodendroglio-trophic properties of cell adhesion molecules in the immunoglobulin superfamily: myelin-associated glycoprotein and N-CAM. J Neurosci Res. 1996;46:415-426.
164. Weiss MD, Hammer J, Quarles RH. Oligodendrocytes in aging mice lacking myelinassociated glycoprotein are dystrophic but not apoptotic. J Neurosci Res. 2000;62:772-780.
165. Trapp BD. Myelin-associated glycoprotein: location and potential functions. Ann N Y Acad Sci. 1990;605:29-43.
166. Salzer JL, Pedraza L, Brown M, Struyk A, Afar D, Bell J. Structure and function of myelinassociated glycoproteins. Ann N Y Acad Sci. 1990;605:302-312.
167. Quarles RH. Myelin-associated glycoprotein in development and disease. Dev Neurosci. 1984; 6:285-303.
168. Filbin MT. Myelin-associated glycoprotein: a role in myelination and in the inhibition of axonal regeneration? Curr Opin Neurobiol. 1995;5:588-595.
169. Coetzee T, Suzuki K, Popko B. New perspectives on the function of myetin gatactolipids. Trends Neurosci. 1998;21:126-130.
170. Koshy KM, Boggs JM. Investigation of the calcium-mediated association between the carbohydrate head groups of galactosylceramide and galactosylceramide 13 sulfate by electrospray ionization mass spectroscopy. J Biol Chem. 1996; 271:3496-3499.
171. Stewart RJ, Boggs JM. A carbohydrate-carbohydrate interaction between galactosylceramide-containing liposomes and cerebroside sulfate-containing liposomes: dependence on the glycolipid ceramide composition. Biochemistry. 1993;32:10666-10674.
172. Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL. GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron. 1996; 17:229-243.
173. Raabe TD, Suy S, Welcher A, DeVries GH. Effect of neu differentiation factor isoforms on neonatal oligodendrocyte function. J Neurosci Res. 1997;50:755-768.
174. De Angelis DA, Braun PE. Binding of 28,38-cyclic nucleotide 38-phosphodiesterase to myelin: an in vitro study. J Neurochem. 1996;66: 2523-2531.
175. De Angelis DA, Braun PE. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase binds to actin-based cytoskeletal elements in an isoprenylationindependent manner. J Neurochem. 1996;67: 943-951.
176. Frank M, van der Haar ME, Schaeren-Weimers N, Schwab ME. rMAL is a glycosphingolipid-associated protein of myelin and apical membranes of epithelial cells in kidney and stomach. J Neurosci. 1998;18:4901-4913.
177. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001; 98:4746-4751.
178. Copland C, Dracheva S, Davis KL, Haroutunian V. mRNA expression of three isoforms of myelin associated glycoprotein (MAG) in patients with schizophrenia [abstract]. Abstr Soc Neurosci. 2002;28:494.4.
179. Bahn S, Starkey M, Jones PB, Emson PC. Gene expression analysis in schizophrenia: reproducible upregulation of several members of the Apolipoprotein I family located in a high susceptibility locus for schizophrenia on chromosome 22. Available at: http://www.stanleylab.org /Document/Bahn's%20absract%202001.htm Accessed November 2002.
180. Faraone SV, Matise T, Svrakic D, Pepple J, Malaspina D, Suarez B, Hampe C, Zambuto CT, Scmitt K, Meyer J, Markel P, Lee H, HarkavyFriedman J, Kaufman C, Cloninger CR, Tsuang MT. Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet. 1998;81:290-295.
181. Mowry BJ, Ewen KR, Nancarrow DJ, Lennon DP, Nertney DA, Jones HL, O'Brien MS, Thornley CE, Walters MK, Crowe RR, Silverman JM, Endicott J, Sharpe L, Hayward NK, Gladis MM, Foote SJ, Levinson DF. Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. Am J Med Genet. 2000; 96:864-869.
182. Levinson DF, Mahtani MM, Nancarrow DJ, Brown DM, Kruglyak L, Kirby A, Hayward NK, Crowe RR, Andreasen NC, Black DW, Silverman JM, Endicott J, Sharpe L, Mohs RC, Siever LJ, Walters MK, Lennon DP, Jones HL, Nertney DA, Daly MJ, Gladis M, Mowry BJ. Genome scan of schizophrenia. Am J Psychiatry. 1998;155:741-750.
183. Williams NM, Rees MI, Holmans P, Norton N, Cardno AG, Jones LA, Murphy KC, Sanders RD, McCarthy G, Gray MY, Fenton I, McGuffin P, Owen MJ. A two-stage genome scan for schizophrenia susceptibility genes in 196 affected sibling pairs. Hum Mol Genet 1999;8:1729-1739.
184. Stober G, Saar K, Ruschendorf F, Meyer J, Nurnberg G, Jatzke S, Franzek E, Reis A, Lesch KP, Wienker TF, Beckmann H. Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet. 2000; 67:1201-1207.
185. Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R, Mankoo BS, Read T, Murphy P, Blaveri E, McQuillin A, Petursson H, Curtis D. Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. Am J Hum Genet. 2001;68: 661-673.
186. Ekelund J, Lichtermann D, Hovatta I, Ellonen P, Suvisaari J, Terwilliger JD, Juvonen H, Varilo T, Arajarvi R, Kokko-Sahin ML, Lonnqvist J, Peltonen L. Genome-wide scan for schizophrenia in the Finnish population: evidence for a locus on chromosome 7q22. Hum Mol Genet. 2000; 9:1049-1057.
187. Bailer U, Leisch F, Meszaros K, Lenzinger E, Willinger U, Strobl R, Gebhardt C, Gerhard E, Fuchs K, Sieghart W, Kasper S, Hornik K, Aschauer HN. Genome scan for susceptibility loci for schizophrenia. Neuropsychobiology. 2000;42:175-182.
188. Brzustowicz LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science. 2000;288:678-682.
189. Kaufman CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, Meyer J, Zambuto CT, Schmitt K, Matise TC, Harkavy Friedman JM, Hampe C, Lee H, Shore D, Wynne D, Faraone SV, Tsuang MT, Cloninger CR. NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet. 1998;81:282-289.
190. Riley BP, Tahir E, Rajagopalan S, MogudiCarter M, Faure S, Weissenbach J, Jenkins T, Williamson R. A linkage study of the N-methylD-aspartate receptor subunit gene loci and schizophrenia in southern African Bantu-speaking families. Psychiatr Genet. 1997;7:57-74.
191. Park JP, Moeschler JB, Berg SZ, Wurster-Hill DH. Schizophrenia and mental retardation in an adult male with a de novo interstitial deletion 9(q32q34.1). J Med Genet. 1991;28:282-283.
192. Lintner RN, Dyer CA. Redistribution of cholesterol in oligodendrocyte membrane sheets after activation of distinct signal transduction pathways. J Neurosci Res. 2000;60:437-449.
193. O'Neill RC, Minuk J, Cox ME, Braun PE, Gravel M. CNP2 mRNA directs synthesis of both CNP1 and CNP2 polypeptides. J Neurosci Res. 1997; 50:248-257.
194. Vogel US, Thompson RJ. Molecular structure, localization and possible functions of the myelin associated enzyme 2′,3′-cyclic nucleotide 3′phosphodiesterase. J Neurochem. 1988;50: 1667-1677.
195. Sprinkle TJ. 2′,3′-Cyclic nucleotide 3′phosphodiesterase, an oligodendrocyteSchwann cell and myelin-associated enzyme of the nervous system. Crit Rev Neurobiol. 1989; 4:235-301.
196. Tsukada Y, Kurihara T. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase: molecular characterization and possible functional significance. In: Martenson RE, ed. Myelin: Biology and Chemistry. Boca Raton, Fla: CRC Press; 1992:449-480.
197. De Angelis D, Cox M, Gao E, Braun PE. Cellular and molecular characteristics of CNP suggest regulatory mechanisms in myelinogenesis. In: Salvati S, ed. A Multidisciplinary Approach to Myelin Diseases II. New York, NY: Plenum Press; 1994:49-58.
198. De Angelis DA, Braun PE. Isoprenylation of brain 2′,3′-cyclic nucleotide 3′-phosphodiesterase modulates cell morphology. J Neurosci Res. 1994;39:386-397.
199. Trapp BD, Quarles R, Suzuki K. Immunocytochemical studies of quaking mice support a role for the myelin-associated glycoprotein in forming and maintaining the periaxonal space and periaxonal cytoplasmic collar of myelinating Schwann cells. J Cell Biol. 1984;99:594-606.
200. Trapp BD, Andrews SB, Cootauco C, Quarles R. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J Cell Biol. 1989;109:2417-2426.
201. Johnson PW, Abramow-Newerly W, Seilheimer B, Sadoul R, Tropak MB, Arquint M, Dunn RJ, Schachner M, Roder JC. Recombinant myelin-associated glycoprotein confers neuronal adhesion and neurite outgrowth function. Neuron 1989;3:377-385.
202. Bartsch U, Kirchhoff F, Schachner M. Immunohistological localization of the adhesion molecules L1, N-CAM, and MAG in the developing and adult optic nerve of mice. J Comp Neurol. 1989;284:451-462.
203. Martini R, Schachner M. Immunoelectron microscopic localization of neural cell adhesion molecules (L1, N-CAM, and MAG) and their shared carbohydrate epitope and myelin basic protein in developing sciatic nerve. J Cell Biol. 1986; 103:2439-2448.
204. Schachner M, Bartsch U. Multiple functions of the myelin-associated glycoprotein MAG (siglec4a) in formation and maintenance of myelin. Glia. 2000;29:154-165.
205. Bartsch U. Myelination and axonal regeneration in the central nervous system of mice deficient in the myelin-associated glycoprotein. J Neurocytol. 1996;25:303-313.
206. Biffiger K, Bartsch S, Montag D, Aguzzi A, Schachner M, Bartsch U. Severe hypomyelination of the murine CNS in the absence of myelinassociated glycoprotein and Fyn tyrosine kinase. J Neurosci. 2000;20:7430-7437.
207. Li C, Tropak MB, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B, Peterson A, Roder J. Myelination in the absence of myelin-associated glycoprotein. Nature. 1994;369:747-750.
208. Lassmann H, Bartsch U, Montag D, Schzchner M. Dying-back oligodendropathy: a late sequel of myelin-associated glycoprotein deficiency. Glia. 1997;19:104-110.
209. Harvey PD, Silverman JM, Mohs RC, Parrella M, White L, Powchik P, Davidson M, Davis KL. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999;45:32-40.
210. Lena JY, Legrand C, Faivre-Sarrailh C, Sarlieve LL, Ferraz C, Rabie A. High gelsolin content of developing oligodendrocytes. Int J Dev Neurosci. 1994;12:375-386.
211. Tanaka J, Kira M, Sobue K. Gelsolin is localized in neuronal growth cones. Dev Brain Res. 1993; 76:268-271.
212. Furukawa K, Fu W, Li Y, Witke W, Kwiatkowski DJ, Mattson MP. The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons. J Neurosci. 1997; 17:8178-8186.
213. Kwiatkowski DJ, Mehl R, Izumo S, Nadal GB, Yin HL. Muscle is the major source of plasma gelsolin. J Biol Chem. 1988;263:8239-8243.
214. Kwiatkowski DJ, Mehl R, Yin HL. Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J Cell Biol. 1988; 106:375-384.
215. Valat J, Privat A, Fulcrand J. Experimental modifications of postnatal differentiation and fate of glial cells related to axo-glial relationships. Int J Dev Neurosci. 1988;6:245-260.
216. Kidd GJ, Hauer PE, Trapp BD. Axons modulate myelin protein messenger RNA levels during central nervous system myelination in vivo. J Neurosci Res. 1990;26:409-418.
217. Barres BA, Raff MC. Proliferation of oligodendrocyte precursor cells depends on electrical activity of axons. Nature. 1993;361:258-259.
218. Hardy R, Reynolds R. Neuron-oligodendroglial interactions during central nervous system development. J Neurosci Res. 1993;36:121-126.
219. Matute C, Sanchez-Gomez M, Martinez-Millan L, Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci U S A. 1997;94:8830-8835.
220. Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, Weinmaster G, Barres BA. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron. 1998;21:63-75.
221. Barres BA, Raff MC. Control of oligodendrocyte number in the developing rat optic nerve. Neuron. 1994;12:935-944.
222. Yang H, Xiao Z, Becker B, Hillenbrand R, Rougon G, Schachner M. Role for myelin-associated glycoprotein as a functional tenascin-R receptor. Neurosci Res. 1999;55:687-701.
223. Bahr M, Bonhoeffer F. Perspectives on axonal regeneration in the mammalian CNS. Trends Neurosci. 1994;17:473-479.
224. Keynes RJ, Cook GM. Repulsive and inhibitory signals. Curr Opin Neurobiol. 1995;5:75-82.
225. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science. 1996;274: 1123-1133.
226. Bergles DE, Roberts JD, Somogyi P, Jahr CE. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature. 2000; 405:187-191.
227. Gallo V, Ghiani CA. Glutamate receptors in glia: new cells, new inputs and new functions. Trends Pharmacol Sci. 2000;21:252-258.
228. Zerangue N, Kavanaugh MP. Flux coupling in a neuronal glutamate transporter. Nature. 1996; 383:634-637.
229. Levy LM, Warr O, Attwell D. Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for low endogenous Na+-dependent glutamate uptake. J Neurosci. 1998;18:9620-9628.
230. Sánchez-Gómez MV, Matute C. AMPA and kainate receptors each mediate excitotoxicity in oligodendrocyte cultures. Neurobiol Dis. 1999;6: 475-485.
231. Burnashev N. Calcium permeability of glutamate gated channels in the central nervous system. Curr Opin Neurobiol. 1996;6:311-317.
232. McDonald JW, Levine JM, Qu Y. Multiple classes of the oligodendrocyte lineage are highly vulnerable to excitotoxicity. Neuroreport. 1998;9: 2757-2762.
233. Matute C. Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci U S A. 1998;95:10229-10234.
234. Choi DW, Maulucci-Gedde M, Kriegstein R. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1987;7:357-368.
235. Frandsen A, Schousboe A. Development of excitatory amino acid induced cytotoxicity in cultured neurons. Int J Dev Neurosci. 1990;8:209-216.
236. Green T, Heinemann SF, Gusella JF. Molecular neurobiology and genetics: investigation of neural function and dysfunction. Neuron. 1998;20: 427-444.
237. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 2001;24:224-230.
238. Yoshioka A, Bacskai B, Pleasure D. Pathophysiology of oligodendroglial excitotoxicity. J Neurosci Res. 1996;46:427-437.
239. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261-1276.
240. Siesio BK. Basic mechanisms of traumatic brain damage. Ann Emerg Med. 1993;22:959-969.
241. Verity MA. Ca(2+)-dependent processes as mediators of neurotoxicity. Neurotoxicology. 1992; 13:139-147.
242. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxiris, and research tools for studying schizophrenia. Neuropsychopharmacology. 1995;13:335-345.
243. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
244. Scheibel AB, Kovelman JA. Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient. Biol Psychiatry. 1981; 16:101-102.
245. Bogerts B, Meertz E, Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volumes and shrinkage. Arch Gen Psychiatry. 1985; 42:784-791.
246. Brown R, Colter N, Corsellis JAN, Crow TJ, Frith CD, Jagoe R, Johnstone EC, Marsh L. Postmortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry. 1986;43:36-42.
247. Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci. 1986;236:154-161.
248. Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: the entorhinal region - a morphometric study. Biol Psychiatry. 1988;24: 515-521.
249. Jeste D, Lohr JB. Hippocampal pathologic findings in schizophrenia. Arch Gen Psychiatry. 1989; 46:1019-1024.
250. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998; 281:1349-1352.
251. Lovinger DM, McCool BA. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol. 1995;73:1076-1083.
252. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921-2927.
253. Deakin JF, Slater P, Simpson MD, Royston MC. Hyperinnervation of orbital frontal cortex in schizophrenia. Br J Psychiatry. 1990;157:459-460.
254. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270-276.
255. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989; 244:1360-1362.
256. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515-1518.
257. Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem Res. 1993; 18:1263-1269.
258. Allen HL, Iversen LL. Phencyclidine, dizocilpine, and cerebrocortical neurons. Science. 1990; 247:221.
259. Fix AS, Horn JW, Wightman KA, Johnson CA, Long GC, Storts RW, Farber NB, Wozniak DF, Olney JW. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol. 1993;123:204-215.
260. Wozniak DF, McEwen M, Sesma MA, Olney JW, Fix AS. MK-801 induces extensive neuronal necrosis in posterior cingulate/retrosplenial cortices [abstract]. Soc Neurosci. 1993;12:1770.
261. Corso T, Neafsey EL, Collins M. Neuron necrotizing properties of phencyclidine [abstract]. Soc Neurosci. 1994;20:1531.
262. Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, Swanson RA, Sagar SM. Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience. 1994;62:1079-1092.
263. Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, Olney JW. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 1997;752:1-14.
264. Farber NB, Price MT, Labruyere J, Fuller TA, Olney JW. Age dependency of NMDA antagonist neurotoxicity [abstract]. Soc Neurosci. 1992;18: 1148.
265. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, Olney JW. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry. 1995;38:788-796.
266. Marshall BE, Longnecker DE. General anesthetics. In: Goodman LS, Gilman A, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. Elmsford, NY: Pergamon Press Inc; 1990:285-310.
267. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci. 1992;12:924-929.
268. A receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience. 1996;75:1021-1031.
269. Akil M, Lewis DA. Reduced dopaminergic innervation of the prefrontal cortex in schizophrenia [abstract]. Soc Neurosci. 1996;22:1679.
270. Lewis DA, Woo T-U, Miller JL, Soloway AS. Schizophrenia and subclasses of local circuit neurons in the prefrontal cortex. Schizophr Res. 1997;24:38-39.
271. Guidotti A, Aura J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E, DiGiorgi Gerevini V. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000; 57:1061-1069.
272. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 1995; 52:258-266.
273. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical γ-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry. 2000;57:237-245.
274. Woo T-U, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal γ-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A. 1998;95: 5341-5346.
275. Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002;159:1165-1173.
276. Dracheva S, Gluck MG, Elhakem SL, Siever L, Davis KL, Haroutunian V. Glutamate synthesis and NMDA receptor and PSD-95 expression in DLPFC and occipital cortices of schizophrenics [abstract]. Abstr Soc Neurosci. 2001;27:335.5.